News

Semaglutide and Vision: What's Real, What's Rare

Creator: Elena Marsh, Health Writer
Published: 2026-09-07

Most people never have an eye problem because of semaglutide. Two things do come up, though, and they get mixed together constantly — so here is what each one actually is.

Elena Marsh, Health Writer September 7, 2026 7 min read

A woman sits in a linen armchair beside a bright window, facing the camera, holding a plain ceramic mug in both hands

The short version

The eye condition people worry about is NAION, a loss of blood supply to the optic nerve. In Danish and Norwegian registry data covering about 61,000 people with type 2 diabetes on semaglutide, it occurred in roughly 2 to 3 people per 10,000 a year.
A May 2026 review pooling 386,207 semaglutide users put the extra risk at about one additional case per 7,000 people treated for a year. European regulators classify it as very rare — up to 1 in 10,000.
Optic nerve anatomy matters more than the drug. In an August 2026 study of 2,169 NAION patients, 94% had a crowded optic disc, and people who had taken a GLP-1 medicine had the same crowded anatomy as people who never had.
A separate and more common issue — diabetic retinopathy briefly worsening when blood sugar falls fast — applies only to people who already have diabetic eye damage: 8.2% versus 5.2% on placebo in the two-year trial behind the label.
The US labels for Ozempic and Wegovy posted in June 2026 carry no NAION warning; Europe added one as a very rare side effect in June 2025. Neither regulator told anyone to stop.
Sudden, painless loss of sight in one eye — often noticed on waking, often the lower half of vision — is the symptom that means same-day care rather than wait-and-see.

Most people who take semaglutide never have a problem with their eyes because of it. That is the honest headline, and it belongs before anything else.

When people search for semaglutide and vision, they are usually circling one of two very different things. One is a rare condition called NAION, essentially a stroke of the optic nerve. The other is diabetic retinopathy getting temporarily worse when blood sugar drops quickly, which only matters if you already have diabetic damage at the back of the eye. Different causes, different odds, different people at risk. Mixing them together is most of what makes this subject frightening.

The rare one: NAION, in plain language

NAION stands for non-arteritic anterior ischemic optic neuropathy — a mouthful for a simple idea. The blood supply to the front of the optic nerve, the cable carrying sight from the eye to the brain, falls short, and part of that nerve is damaged. People usually notice on waking: sight in one eye suddenly dimmed or partly missing, often the lower half, and it does not hurt.

The most useful real-world numbers come from national health registries in Denmark and Norway, where researchers followed about 61,000 people with type 2 diabetes starting semaglutide against people starting a different diabetes drug. Across both countries, 32 cases turned up. In Denmark the rate was 2.19 per 10,000 person-years on semaglutide against 1.18 on the comparison drug; in Norway, 2.90 against 0.92. Pooled, that is a hazard ratio of 2.81 — roughly 1.4 extra cases per 10,000 people a year (Diabetes, Obesity and Metabolism, 2025).

Double a very small number is still a very small number. That is the shape of this whole topic.

A review published in May 2026 pooled five studies covering 386,207 people on semaglutide against 626,406 on something else, and landed on a hazard ratio of 2.17 — about one extra case for every 7,000 people treated for a year. The authors graded their own evidence as low to very low certainty (PLOS Medicine, 2026).

The study that started the alarm was narrower. In 2024, neuro-ophthalmologists at Mass Eye and Ear looked back through their own clinic records and reported steeper hazard ratios — 4.28 in patients with type 2 diabetes, 7.64 in patients who were overweight or obese (JAMA Ophthalmology, 2024). Worth knowing where those came from: a specialist clinic people are sent to precisely because something has gone wrong with their optic nerve.

Semaglutide and vision risk turns on your own optic nerve

As of September 6, 2026, the day this article was written, the newest work here is a study published in Ophthalmology on August 5, 2026 by sixteen neuro-ophthalmology centres calling themselves the Disc-at-Risk Study Group. They examined the unaffected eye of 2,169 people who had already had NAION in the other one, alongside 465 people who never had it.

What they measured was the cup-to-disc ratio: how much spare room there is where the optic nerve enters the eye. A small ratio means a crowded disc — a lot of nerve fibres squeezed through a narrow opening.

Almost everyone with NAION had one. In 94% of the unaffected eyes the ratio was 0.40 or lower, against 56% of the comparison eyes. At the tightest end, 0.20 or lower, the odds ran about 46 times higher than in roomier eyes.

Then the part that reframes the conversation. The crowding was the same whether or not the person had ever taken a GLP-1 medicine. The authors are careful that their work does not settle whether these medicines add risk of their own — but it says plainly that the anatomy is doing most of it (Ophthalmology, 2026). A companion paper in the same journal in June 2026 asked the same question in people with optic disc drusen, small deposits that crowd the nerve head a different way (Ophthalmology, 2026).

Which has an unusually concrete end: an eye doctor can look at the back of your eye in a few minutes and tell you whether you have a crowded disc. Most people do not.

The other one: fast blood-sugar drops and the retina

Different mechanism, and the risk is concentrated in people who already have diabetic damage to the retina, the light-sensitive lining at the back of the eye: in the two-year trial the Wegovy label cites, complications occurred in 8.2% versus 5.2% of those with a history of retinopathy and 0.7% versus 0.4% of those without one. When blood sugar has run high for a long time and then falls quickly, existing retinopathy can worsen for a while before settling — a known effect of improving glucose control in general, not something semaglutide invented.

The label numbers come from a two-year trial in adults with type 2 diabetes and high cardiovascular risk. Retinopathy complications occurred in 3.0% of people on semaglutide and 1.8% on placebo. Split by who already had eye damage it gets clearer: 8.2% versus 5.2% among those who had retinopathy at the start, and 0.7% versus 0.4% among those who did not. Nearly the whole difference sits with people who came in with diabetic eye disease.

If that is you, this — not NAION — is what a provider will want a recent eye exam for. Semaglutide for type 2 diabetes covers that side of the decision.

What the labels actually say

As of September 6, 2026, the day this article was written, the US prescribing information for Ozempic and Wegovy — the versions posted to the FDA's DailyMed label database in June 2026 — does not mention NAION or the optic nerve anywhere. Both carry the diabetic retinopathy section above.

Europe read the same evidence differently. In June 2025 the European Medicines Agency's safety committee asked for NAION to be added to the product information for Ozempic, Rybelsus and Wegovy as a very rare side effect — its category for something that may affect up to 1 in 10,000 people. Same molecule, same studies, two regulators weighing them differently.

FDA's review did not direct anyone to stop. EMA's committee did add one instruction: if NAION is confirmed, treatment with semaglutide should be stopped (EMA, June 2025). Regulatory status is one input into a prescribing decision rather than the whole of it, and a licensed provider may still prescribe where they judge it appropriate — that decision is between you and your doctor.

One thing to be precise about: through Promise, semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product — the formulation offered here is not FDA-approved. Compounded semaglutide unpacks what that does and does not mean.

Does any of this apply to tirzepatide?

Partly, and less. A comparison of adverse-event reports published in June 2026 examined six medicines in this family. Semaglutide carried by far the strongest reporting signal for optic nerve ischaemia, with 355 reports; tirzepatide had 49 and liraglutide 13, and three other drugs in the class showed no signal at all — which argues against a simple class effect (Diabetes, Obesity and Metabolism, 2026). Reporting databases cannot tell you risk, though. They collect what people happened to report, and a drug in the news gets reported more.

On the retinopathy side, tirzepatide caught up this year: the Mounjaro prescribing information added a diabetic retinopathy section in August 2026.

The symptoms that mean call today

Not every visual oddity is an emergency. Blurring that comes and goes in both eyes early on is common, and usually traces back to blood sugar moving rather than to damage — semaglutide side effects covers the ordinary ones.

These are different:

Sudden loss of sight in one eye, with no pain, often noticed first thing in the morning
A dark, grey or missing patch in part of your field of view, frequently the lower half
Vision in one eye that drops and does not come back within minutes

Any of those is a same-day call to a doctor or an eye casualty department. There is no established treatment that reverses NAION once it has happened, and a sudden change in sight has several other possible causes — some treatable if caught quickly.

What a provider will want to know

A licensed provider reviews every request and prescribes only when it is appropriate for you; not everyone qualifies. On the eye side, the details worth volunteering: whether you have ever had NAION in either eye, whether you have diabetes and when you last had a dilated eye exam, and whether anyone has told you your optic disc is small, crowded, or has drusen. For the wider picture, is semaglutide safe covers the ground this page does not.

None of this is a reason to be frightened of a medicine you and a doctor decided was worth trying. It is a reason to know what your own optic nerves look like, and to speak up the same day if your sight changes.

Common questions

Can semaglutide cause permanent vision loss?

It is rare, but NAION — a loss of blood supply to the optic nerve — can leave lasting damage in the affected eye. In national registry data from Denmark and Norway, NAION occurred in roughly 2 to 3 people per 10,000 each year on semaglutide, against about 1 per 10,000 on a comparison diabetes drug. Sudden painless loss of sight in one eye needs same-day medical attention.

What are the first signs of NAION?

Sudden, painless loss of sight in one eye, usually noticed on waking. People tend to describe a dark or missing patch rather than overall blurring, and it commonly affects the lower half of the field of view. There is no pain and no redness. Any sudden change in sight in one eye is a same-day call, not a wait-and-see.

Does semaglutide cause blurry vision?

Blurring is common early on, and it usually comes from blood sugar changing rather than from damage to the eye. As glucose levels shift, the lens changes shape slightly and focus moves with it, which typically settles as levels stabilise. Blurring in both eyes that comes and goes is a different thing from sudden loss of sight in one eye, which is urgent.

Is NAION listed on the US semaglutide label?

Not as of September 6, 2026. The US prescribing information for Ozempic and Wegovy posted to the FDA's DailyMed database in June 2026 does not mention the optic nerve at all. Both do carry a section on diabetic retinopathy complications. In June 2025 the European Medicines Agency asked for NAION to be added to the European product information as a very rare side effect.

Should I get an eye exam before starting semaglutide?

If you have diabetes, a recent dilated eye exam is a reasonable thing to have in hand, because existing diabetic retinopathy can worsen temporarily when blood sugar falls quickly. Separately, an eye doctor can tell you whether you have a crowded optic disc — the anatomy that carried roughly 46 times the odds of NAION in a 2026 study of 2,169 patients. Your provider decides what is needed in your case.

Is compounded semaglutide FDA-approved?

No. FDA-approved semaglutide products exist — Ozempic, Wegovy and Rybelsus — but the compounded formulation offered here is not FDA-approved. It is the same molecule, prepared for an individual patient by a licensed U.S. compounding pharmacy on a prescription rather than manufactured as a branded product.